Centessa Pharmaceuticals plc CNTA

Eli Lilly is set to acquire Centessa Pharmaceuticals for approximately $6.3 billion, a strategy aimed at enhancing its pipeline with advanced orexin receptor 2 agonists addressing neurological disorders. This acquisition will provide access to Centessa's innovative drug candidates, including those currently in Phase II trials, while aligning with Lilly's commitment to transformative treatment options. Centessa, recently valued at $1.72 billion, continues its development of medicines designed to improve patient lives, solidifying its role in the expanding neuroscience therapeutics market.